MGC beefs up epilepsy expertise
MGC Pharmaceutical (ASX:MXC) has added intellectual weight to its fight against severe epilepsy as it ramps up stakeholder engagement with a focus on medical cannabis’ role in combating the disease.
It told its shareholders this morning that Israeli-bases Dr Uri Kramer has joined the company as a member of its strategic advisory board – which will guide the company on establishing clinical trials using medical cannabis in the treatment of severe epilepsy.
Dr Kramer is a highly regarded expert in the field of paediatric neurology and paediatric epilepsy — and he’ll join Australian cardiologist Dr Ross Walker on the design of trials and product development.
MXC has focused its pharmaceutical efforts on treating epilepsy, entering into a research agreement with SipNose back in March, with the agreement around the development of a cannabinol (CBD)-based treatment to be delivered through the Sipnose device.
The pair have set up in the Hadassah Medical Centre in Israel – but the signing of Dr Kramer further demonstrates its pharmaceutical intent.
MXC also has a line of CBD-based cosmetic products in the market which helps deliver underlying revenue to the company.
These include facial creams, eye serums, soaps, toners, and cleansing milks with compounds derived from medical cannabis.
On the lobbying front
MXC has stepped up its lobbying effort in Australia in an effort to allow the company to conduct clinical trials and ultimately have something of a first-mover advantage in the country.
It has previously teamed up with the University of Sydney to study the market potential of the Australian medical cannabis market – with a white paper finding that it was a $150 million opportunity.
A series of both state and federal moves on the relaxation of restrictive regulations around medical cannabis has opened the doors for medical cannabis players such as MXC to potential make a market entry.
It should be noted that regulations are not set in stone and are able to be changed – investors should seek independent advice before deciding whether or not to invest.
The appointment of Dr Kramer will help establish its credentials in the Australian market and elsewhere as a market-leader in the use of medical cannabis to treat epilepsy.
MXC said that it had started the stakeholder engagement process, including talks with state and federal governments, medical professionals, academics, and other industry participants.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.